ISSUE
9 SEPTEMBER 2012
E-NEWSLETTER OF THE UNIVERSITY OF TOLEDO COLLEGE OF PHARMACY AND PHARMACEUTICAL SCIENCES
RxeFILL this issue Dr. Hacker’s Cancer Drug P.1 PCAT Test at UT P.2
George E. Bush Park Honors UT Alumnus
New Cosmetic Science Major P.3 Upcoming Events P.4
The life and work of George E. Bush, a 1930 UT Pharmacy graduate and Toledo community
Dr. Hacker sees cancer drug approved for use
pharmacist, were recognized through the naming of a new playground and park in his honor. Along with caring for patients, Bush was known for giving children free ice cream at his pharmacy. Dean Early attended the park dedication near Spring Elementary; the event was hosted by Toledo Mayor Mike Bell. Although Mr. Bush passed away in 1976, the memory of his impact on the local community is reaching yet another generation. See the story published in The Blade.
Dr. Miles Hacker, Professor and Master Teacher in the Department of Pharmacology, is now able to see the fruits of his labor in the form of a cancer drug on the market. The medication, Pixantrone, was recently approved for use in Europe, nearly 20 years after it first demonstrated effectiveness against tumor growth. Pixantrone is a topoisomerase II, a drug that inhibits DNA synthesis of cancer cells and damages cancer cell DNA through apoptosis, the natural process of cell death. Pixantrone is considered a safer alternative to doxorubicin, a cancer drug with a similar mechanism of action, because it does not cause damage to the heart.
The drug has been proven clinically effective in the treatment of non-Hodgkins lymphoma and leukemia and is the only drug that has been proven effective for patients with severe, late-stage non-Hodgkins lymphoma. Currently being tested for effectiveness against metastatic breast cancer and multiple sclerosis, Pixantrone is a promising treatment for these devastating diseases. About Dr. Hacker and his work